Aulos Bioscience to Present Phase 2 Data for Imneskibart With Avelumab in Adenocarcinoma Non-Small Cell Lung Cancer at ESMO Congress 2026

LARKSPUR, Calif.--(BUSINESS WIRE)--Aulos Bioscience, an immuno-oncology company working to revolutionize cancer care through development of its lead immune-activating antibody therapeutic imneskibart (AU-007), today announced that new Phase 2 data for imneskibart with avelumab in checkpoint inhibitor (CPI)-refractory adenocarcinoma non-small cell lung cancer (NSCLC) will be presented at the European Society for Medical Oncology (ESMO) Congress 2026. The congress is being held October 23-27, 2026, in Madrid, Spain.

Details of the poster presentation are as follows:

Title: Imneskibart (AU-007) + low-dose SC IL-2 + avelumab: Phase 2 activity in CPI-refractory advanced adenocarcinoma NSCLC
Abstract: 6280
Presentation Number: 2573P
Session Title: Poster Display session, NSCLC, locally advanced
Date and Time: Monday, October 26, 2026, 12:00 p.m.-12:45 p.m. CET

The abstract will be published online via the ESMO website at 12:05 a.m. CEST on October 19, 2026. The poster will be presented in Poster Area – Hall 5 at the IFEMA MADRID. An electronic version will also be available on the ESMO Congress 2026 virtual platform.

About Imneskibart

Imneskibart (AU-007) is a human IgG1 monoclonal antibody designed by leveraging artificial intelligence that is highly selective to the CD25-binding portion of IL-2. With a mechanism of action unlike any other IL-2 therapeutic in development, imneskibart redirects IL-2 to reinforce anti-tumor immune effects. This is achieved by preventing IL-2, either exogenous or secreted by effector T cells, from binding to trimeric receptors on regulatory T cells while still allowing IL-2 to bind and expand effector T cells and NK cells. This prevents the negative feedback loop caused by other IL-2-based treatments and biases the immune system toward activation over suppression. Imneskibart also prevents IL-2 from binding to CD25-containing receptors on eosinophils, as well as vasculature and pulmonary endothelium, which may significantly reduce the vascular leak syndrome and pulmonary edema associated with high-dose IL-2 therapy.

To learn more about the imneskibart Phase 1/2 clinical trial program, including study locations in the United States and Australia, please visit ClinicalTrials.gov (identifier: NCT05267626), www.solidtumorstudy.com (U.S.) and www.solidtumourstudy.com (Australia).

About Aulos

Aulos Bioscience is an immuno-oncology company working to revolutionize cancer patient care through immune-activating antibody therapeutics that direct patients’ immune systems toward killing tumor cells. Matching world-class machine learning from co-founder Biolojic Design with an in-depth understanding of the immune system, Aulos’ initial clinical candidate, imneskibart (AU-007), is a human antibody designed by leveraging artificial intelligence that harnesses the power of IL-2 to induce tumor killing while limiting the immunosuppression and toxicities typically associated with this validated pathway. The company was founded by Biolojic Design and Apple Tree Partners (ATP) and is led by pioneers in the fields of artificial intelligence, antibody development and cancer immunotherapies. For more information, visit www.aulos.com, X (@AulosBioscience) and LinkedIn.